Several subtypes of avian influenza viruses (AIVs) are emerging as novel human pathogens, and the frequency of related infections has increased in recent years. Although neuraminidase (NA) inhibitors (NAIs) are the only class of antiviral drugs available for therapeutic intervention for AIV-infected patients, studies on NAI resistance among AIVs have been limited and markers of resistance are poorly understood. Previously, we identified unique NAI-resistance substitutions in AIVs of N3, N7, and N9 NA subtypes. Here, we report profiles of NA substitutions that confer NAI resistance in the AIVs of N4, N5, N6, and N8 NA subtypes using Gene-fragmented Random Mutagenesis. We generated libraries of mutant influenza viruses using reverse genetics (RG), and selected resistant variants in the presence of the NAIs oseltamivir carboxylate and zanamivir in MDCK cells. In addition, two substitutions, H274Y or R292K (N2 numbering) were introduced into each NA gene for comparison. We identified 37 amino acid substitutions within the NA gene, 16 of which (N4 = 4, N5 = 4, N6 = 4, and N8 = 4) conferred resistance to NAIs (oseltamivir carboxylate, zanamivir, or peramivir) as determined using a fluorescence-based NA inhibition assay. Substitutions conferring NAI resistance were mainly categorized as either novel NA subtype-specific (G/N147V/I, A246V and I427L) or previously reported in other subtypes (E119A/D/G/V, Q136K, E276D, R292K, and R371K). Our results demonstrate that each NA subtype possesses unique NAI resistance markers and knowledge of these substitutions in AIVs is important in facilitating antiviral susceptibility monitoring of NAI resistance in AIVs.IMPORTANCE The frequency of human infections with avian influenza viruses (AIVs) has increased in recent years. Despite the availability of vaccines, neuraminidase inhibitors (NAIs)-as the only available class of drugs for AIVs in humans-have been constantly used for treatment leading to the inevitable emergence of drug-resistant variants. To screen for substitutions conferring NAI resistance in AIV of N4, N5, N6, and N8 NA subtypes, random mutations within the target gene were generated and resistant viruses were selected from mutant libraries in the presence of individual drugs. We identified 16 NA substitutions conferring NAI resistance in the tested AIV subtypes, some are novel and subtype-specific, and others have been previously reported in other subtypes. Our findings will contribute to an increased and more comprehensive understanding of the mechanisms of NAI-induced inhibition of influenza and help lead to the development of drugs that bind to alternative interaction motifs.